Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Sep 02, 16:00
Kezar Life Sciences Research and Development Expense (TTM) : 23.12M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 23.12M |
| December 31, 2025 | 33.76M |
| September 30, 2025 | 44.71M |
| June 30, 2025 | 54.04M |
| March 31, 2025 | 60.75M |
| December 31, 2024 | 65.74M |
| September 30, 2024 | 72.35M |
| June 30, 2024 | 79.85M |
| March 31, 2024 | 84.55M |
| December 31, 2023 | 85.78M |
| September 30, 2023 | 77.99M |
| June 30, 2023 | 68.12M |
| March 31, 2023 | 58.46M |
| December 31, 2022 | 51.09M |
| September 30, 2022 | 45.75M |
| June 30, 2022 | 42.52M |
| March 31, 2022 | 40.52M |
| Date | Value |
|---|---|
| December 31, 2021 | 38.78M |
| September 30, 2021 | 37.38M |
| June 30, 2021 | 35.00M |
| March 31, 2021 | 32.81M |
| December 31, 2020 | 30.98M |
| September 30, 2020 | 30.30M |
| June 30, 2020 | 29.12M |
| March 31, 2020 | 28.89M |
| December 31, 2019 | 27.36M |
| September 30, 2019 | 24.60M |
| June 30, 2019 | 22.19M |
| March 31, 2019 | 20.49M |
| December 31, 2018 | 18.14M |
| September 30, 2018 | 15.10M |
| June 30, 2018 | 11.99M |
| March 31, 2018 | 8.21M |
| December 31, 2017 | 6.469M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.297M |
| Summit Therapeutics, Inc. | 568.74M |
| Protara Therapeutics, Inc. | 52.89M |
| Clene, Inc. | 11.48M |